Minnelide

Drug Profile

Minnelide

Alternative Names: 14-O-phosphonooxymethyltriptolide-disodium-salt; Minnelide; Minnelide-001

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Minnesota
  • Developer Barts and The London NHS Trust; Minneamrita Therapeutics; Queen Mary University of London; Translational Genomics Research Institute
  • Class Antineoplastics; Diterpenes; Epoxy compounds; Phenanthrenes; Phosphoric acid esters
  • Mechanism of Action HSP70 heat shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Gastrointestinal cancer

Most Recent Events

  • 28 Apr 2017 Minneamrita Therapeutics plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in USA (NCT03129139)
  • 10 Apr 2017 Phase-II clinical trials in Pancreatic cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03117920)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top